Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Daniel Grosslight has maintained a Neutral rating on Teladoc Health (NYSE:TDOC) and lowered the price target from $31 to $29.
July 26, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has maintained a Neutral rating on Teladoc Health and lowered the price target from $31 to $29.
The lowering of the price target by Citigroup indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Teladoc Health's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100